Is Pyxis Oncology Stock a Good Investment?
Pyxis Oncology Investment Advice | PYXS |
- Examine Pyxis Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pyxis Oncology's leadership team and their track record. Good management can help Pyxis Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Pyxis Oncology's business and its evolving consumer preferences.
- Compare Pyxis Oncology's performance and market position to its competitors. Analyze how Pyxis Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Pyxis Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pyxis Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pyxis Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pyxis Oncology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pyxis Oncology Stock
Researching Pyxis Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 25.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pyxis Oncology has Price/Earnings To Growth (PEG) ratio of 0.01. The entity recorded a loss per share of 1.06. The firm had not issued any dividends in recent years.
To determine if Pyxis Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pyxis Oncology's research are outlined below:
| Pyxis Oncology generated a negative expected return over the last 90 days | |
| Pyxis Oncology has high historical volatility and very poor performance | |
| Pyxis Oncology may become a speculative penny stock | |
| Pyxis Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (73.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pyxis Oncology currently holds about 223.36 M in cash with (70.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pyxis Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Pyxis Oncologys SWOT analysis ADC innovators stock poised for growth |
Pyxis Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pyxis Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pyxis Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pyxis Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pyxis Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.31 | -0.35 | -0.04 | 12 | ||
2024-03-21 | 2023-12-31 | -0.47 | -0.33 | 0.14 | 29 | ||
2024-05-14 | 2024-03-31 | -0.24 | -0.06 | 0.18 | 75 | ||
2023-08-11 | 2023-06-30 | -0.65 | -0.41 | 0.24 | 36 | ||
2023-05-11 | 2023-03-31 | -0.9 | -0.55 | 0.35 | 38 | ||
2022-05-13 | 2022-03-31 | -0.61 | -0.97 | -0.36 | 59 | ||
2022-03-29 | 2021-12-31 | -0.37 | -1.98 | -1.61 | 435 | ||
2021-11-15 | 2021-09-30 | -0.51 | -8.96 | -8.45 | 1656 |
Know Pyxis Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pyxis Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pyxis Oncology backward and forwards among themselves. Pyxis Oncology's institutional investor refers to the entity that pools money to purchase Pyxis Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perceptive Advisors Llc | 2024-09-30 | 508.5 K | 683 Capital Management Llc | 2024-09-30 | 414.7 K | Northern Trust Corp | 2024-09-30 | 394 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 382.8 K | Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 382.6 K | Decheng Capital Llc | 2024-06-30 | 326.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 311.6 K | Boothbay Fund Management, Llc | 2024-09-30 | 283.6 K | Citadel Advisors Llc | 2024-09-30 | 276 K | Deep Track Capital, Lp | 2024-09-30 | 4.2 M | Laurion Capital Management Lp | 2024-09-30 | 3.6 M |
Pyxis Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 112.39 M.Market Cap |
|
Pyxis Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.52) | |
| Return On Capital Employed | (0.56) | (0.58) | |
| Return On Assets | (0.42) | (0.45) | |
| Return On Equity | (0.59) | (0.56) |
Determining Pyxis Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Pyxis Oncology is a good buy. For example, gross profit margin measures Pyxis Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pyxis Oncology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pyxis Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pyxis Oncology. Check Pyxis Oncology's Beneish M Score to see the likelihood of Pyxis Oncology's management manipulating its earnings.
Evaluate Pyxis Oncology's management efficiency
Pyxis Oncology has return on total asset (ROA) of (0.2106) % which means that it has lost $0.2106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3934) %, meaning that it created substantial loss on money invested by shareholders. Pyxis Oncology's management efficiency ratios could be used to measure how well Pyxis Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.58 in 2024. At this time, Pyxis Oncology's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 16.4 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 111 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.15 | 2.50 | |
| Tangible Book Value Per Share | 2.54 | 2.40 | |
| Enterprise Value Over EBITDA | (1.06) | (1.12) | |
| Price Book Value Ratio | 0.57 | 0.60 | |
| Enterprise Value Multiple | (1.06) | (1.12) | |
| Price Fair Value | 0.57 | 0.60 | |
| Enterprise Value | 83.5 M | 79.3 M |
The management strategies employed by Pyxis Oncology's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.276 |
Basic technical analysis of Pyxis Stock
As of the 26th of November, Pyxis Oncology holds the Variance of 49.48, risk adjusted performance of (0.07), and Coefficient Of Variation of (995.54). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pyxis Oncology, as well as the relationship between them. Please check Pyxis Oncology risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Pyxis Oncology is priced some-what accurately, providing market reflects its current price of 1.89 per share. Please also confirm Pyxis Oncology jensen alpha, which is currently at (0.73) to check out the company can sustain itself at a future point.Pyxis Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pyxis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pyxis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pyxis Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pyxis Oncology's Outstanding Corporate Bonds
Pyxis Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pyxis Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pyxis bonds can be classified according to their maturity, which is the date when Pyxis Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| QORVO INC 3375 Corp BondUS74736KAJ07 | View | |
| QORVO INC 4375 Corp BondUS74736KAH41 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| QTELQD 2625 08 APR 31 Corp BondUS74735KAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Pyxis Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pyxis Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (4.72) | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (995.54) | |||
| Standard Deviation | 7.03 | |||
| Variance | 49.48 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (1.81) | |||
| Treynor Ratio | (4.73) | |||
| Maximum Drawdown | 61.13 | |||
| Value At Risk | (8.17) | |||
| Potential Upside | 6.41 | |||
| Skewness | (3.67) | |||
| Kurtosis | 24.4 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (4.72) | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (995.54) | |||
| Standard Deviation | 7.03 | |||
| Variance | 49.48 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (1.81) | |||
| Treynor Ratio | (4.73) | |||
| Maximum Drawdown | 61.13 | |||
| Value At Risk | (8.17) | |||
| Potential Upside | 6.41 | |||
| Skewness | (3.67) | |||
| Kurtosis | 24.4 |
Consider Pyxis Oncology's intraday indicators
Pyxis Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pyxis Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pyxis Oncology time-series forecasting models is one of many Pyxis Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pyxis Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Pyxis Stock media impact
Far too much social signal, news, headlines, and media speculation about Pyxis Oncology that are available to investors today. That information is available publicly through Pyxis media outlets and privately through word of mouth or via Pyxis internal channels. However, regardless of the origin, that massive amount of Pyxis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pyxis Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pyxis Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pyxis Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pyxis Oncology alpha.
Pyxis Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pyxis Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pyxis Oncology Corporate Management
| Balu Balasubramanian | Interim Officer | Profile | |
| Jan Pinkas | Chief Officer | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Charles Gombar | Senior Management | Profile | |
| MBA MBA | CoFounder Chairman | Profile | |
| MD FACP | Chief Officer | Profile | |
| Jitendra Wadhane | Senior Officer | Profile |
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.